Ridinilazole 是一种新型的窄谱非吸收性抗生素。它显示出对艰难梭菌的有效抑制作用 (MIC90=0.125 mg/L)，并且比甲硝唑 (MIC90?=?8 mg/L) 或万古霉素 (MIC90?=?2 mg/L) 更有效。

Ridinilazole is a novel narrow-spectrum nonabsorbable antibiotic. Ridinilazole showed potent inhibition of C. difficile (MIC90=0.125 mg/L) and was markedly more active than either metronidazole (MIC90 = 8 mg/L) or vancomycin (MIC90 = 2 mg/L).

ridinilazole , a novel antibacterial currently under development for the treatment of CDI.?Owing to its highly targeted spectrum of activity and ability to spare the normal gut microbiota, ridinilazole provides significant advantages over metronidazole and vancomycin, the mainstay antibiotics for CDI.?Ridinilazole is bactericidal against C. difficile and exhibits a prolonged post-antibiotic effect.?Furthermore, treatment with ridinilazole results in decreased toxin production.

308362-25-6

C24H16N6

388.42

SMT19969;Ridinilazole

DMSO:55 mg/mL (141.6 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years